← Leaderboards
G Caleb Alexander
Johns Hopkins University
$18,620,966
Attributed
$21,184,726
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$13,556,027 · 2
NIH$5,127,521 · 2
AHRQ$2,101,365 · 2
CDC$399,813 · 1
By mechanism
U01$13,955,840 · 3
R01$4,483,649 · 2
T32$2,128,600 · 1
K08$616,637 · 1
Top collaborators
- Jodi B Segal7 shared
- Sherry L Emery4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Arthur L. Burnett$7,988,264
- Jonathan M. Samet$20,576,555
- Darcy Ann Thompson$5,446,939
- Wayne Mitzner$20,452,046
- Robert H Brown$6,811,046
Others in their field
Top investigators on “Pharmacoepidemiology”
- Sean P Hennessy · University Of Pennsylvania$17,900,192
- Kathleen Mullan Harris · Duke University$17,567,474
- Brian Leslie Strom · University Of Pennsylvania$12,122,571
- Charles M. Stein · Vanderbilt University$11,293,690
- Lang Li · Indiana Univ-Purdue Univ At Indianapolis$9,459,048
- Allen A Mitchell · Boston University Medical Campus$9,414,760
Research focus
PharmacoepidemiologyTraining ProgramsNational Heart, Lung, And Blood InstituteAdvocateAreaArthritisAmericanBaseBehavioralBenefits And RisksCategoriesCharacteristicsChronicCodeCommunitiesCollectionComparativeComplexConsensusConsumer BehaviorData SetDensityDirect To Consumer AdvertisingAsthma
Grant awards (51)
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$415,589
U01 · FY2025 · FD · contact PI
NHLBI Training Program in Pharmacoepidemiology$339,844
T32 · FY2025 · HL · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$786,317
U01 · FY2024 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$432,530
U01 · FY2024 · FD · contact PI
NHLBI Training Program in Pharmacoepidemiology$317,361
T32 · FY2024 · HL · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$303,001
U01 · FY2024 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$300,000
U01 · FY2024 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$260,375
U01 · FY2024 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$259,411
U01 · FY2024 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$250,000
U01 · FY2024 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$171,941
U01 · FY2024 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$94,985
U01 · FY2024 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$514,763
U01 · FY2023 · FD · contact PI
NHLBI Training Program in Pharmacoepidemiology$212,451
T32 · FY2022 · HL · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JH-CERSI)$207,628
U01 · FY2022 · FD · contact PI
NHLBI Training Program in Pharmacoepidemiology$354,642
T32 · FY2021 · HL · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JH-CERSI)$207,628
U01 · FY2021 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JH-CERSI)$21,425
U01 · FY2021 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JH-CERSI)$1,462,131
U01 · FY2020 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JH-CERSI)$1,364,159
U01 · FY2020 · FD · contact PI
NHLBI Training Program in Pharmacoepidemiology$347,125
T32 · FY2020 · HL · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JH-CERSI)$1,091,848
U01 · FY2019 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JH-CERSI)$442,369
U01 · FY2019 · FD · contact PI
NHLBI Training Program in Pharmacoepidemiology$307,722
T32 · FY2019 · HL · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation (JH-CERSI)$2,122,598
U01 · FY2018 · FD · contact PI
NHLBI Training Program in Pharmacoepidemiology$249,455
T32 · FY2018 · HL · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$154,522
U01 · FY2018 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$75,178
U01 · FY2018 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$23,587
U01 · FY2018 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$808,901
U01 · FY2017 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$60,000
U01 · FY2017 · FD · contact PI
Johns Hopkins Center of Excellence in Regulatory Science and Innovation$571,075
U01 · FY2016 · FD · contact PI
ENHANCING REGULATORY SCIENCE THROUGH A UNIQUE FDA-ACADEMIC PARTNERSHIP$670,769
U01 · FY2015 · FD · contact PI
IMPACT OF "PILL MILL" LAWS ON OPIOID PRESCRIBING, DISPENSING AND UTILIZATION$199,829
U01 · FY2015 · CE · contact PI
ENHANCING REGULATORY SCIENCE THROUGH A UNIQUE FDA-ACADEMIC PARTNERSHIP$100,000
U01 · FY2015 · FD · contact PI
Televised Direct to Consumer Pharmaceutical Advertising and Patient Outcomes$733,991
R01 · FY2014 · HL
ENHANCING REGULATORY SCIENCE THROUGH A UNIQUE FDA-ACADEMIC PARTNERSHIP$294,544
U01 · FY2014 · FD · contact PI
IMPACT OF "PILL MILL" LAWS ON OPIOID PRESCRIBING, DISPENSING AND UTILIZATION$199,984
U01 · FY2014 · CE · contact PI
ENHANCING REGULATORY SCIENCE THROUGH A UNIQUE FDA-ACADEMIC PARTNERSHIP$88,753
U01 · FY2014 · FD · contact PI
Televised Direct to Consumer Pharmaceutical Advertising and Patient Outcomes$716,055
R01 · FY2013 · HL
Televised Direct to Consumer Pharmaceutical Advertising and Patient Outcomes$764,611
R01 · FY2012 · HL
Assessing the effect of FDA advisories on provider, patient, and firm behavior$499,104
R01 · FY2012 · HS · contact PI
Televised Direct to Consumer Pharmaceutical Advertising and Patient Outcomes$784,264
R01 · FY2011 · HL
Assessing the effect of FDA advisories on provider, patient, and firm behavior$420,658
R01 · FY2011 · HS · contact PI
Assessing the effect of FDA advisories on provider, patient, and firm behavior$70,501
R01 · FY2011 · HS · contact PI
Assessing the effect of FDA advisories on provider, patient, and firm behavior$494,465
R01 · FY2010 · HS · contact PI
An RCT To Decrease Out-Of-Pocket Prescription Costs$120,620
K08 · FY2010 · HS · contact PI
An RCT To Decrease Out-Of-Pocket Prescription Costs$124,200
K08 · FY2009 · HS · contact PI
An RCT To Decrease Out-Of-Pocket Prescription Costs$124,443
K08 · FY2008 · HS · contact PI
An RCT To Decrease Out-Of-Pocket Prescription Costs$124,524
K08 · FY2007 · HS · contact PI
An RCT To Decrease Out-Of-Pocket Prescription Costs$122,850
K08 · FY2006 · HS · contact PI